Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
Mar 13, 2024
Read MoreZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
Mar 06, 2024
Read MoreZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
Feb 27, 2024
Read MoreZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
Jan 25, 2024
Read MoreZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Jan 10, 2024
Read More